Know what’s really happening at
Arnatar Therapeutics before you sign on.
- On the roadmap
- RNA Therapeutics
- Drug Discovery
- Biotechnology
Arnatar Therapeutics is building a nucleic acid therapeutics platform capable of both upregulating and downregulating genes, targeting high unmet needs in cardiovascular, metabolic, and organ-specific diseases. Founded in 2022 and backed by top-tier investors, the San Diego-based company is advancing RNA-based medicines toward clinical development.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
Arnatar Therapeutics
- Year Founded
- 2022
- Series A Round
- $52M
- Total Funding
- ~$66.3M
- Headquarters
- San Diego, California, United States
- Company Size
- 11-50
- Funding Rounds
- 2
- Growth Signal
- Headcount Surge
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- RNA Therapeutics landscape
- RNA Therapeutics growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- Arnatar Therapeutics TAM
- RNA Therapeutics market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does Arnatar Therapeutics do
- Arnatar Therapeutics product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- Arnatar Therapeutics customers
- who uses Arnatar Therapeutics
- Arnatar Therapeutics ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- Arnatar Therapeutics competitors
- Arnatar Therapeutics alternatives
- who competes with Arnatar Therapeutics
- Arnatar Therapeutics win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- Arnatar Therapeutics reviews
- Arnatar Therapeutics NRR
- Arnatar Therapeutics churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- Arnatar Therapeutics investment thesis
- Arnatar Therapeutics moat
- bull case bear case
- Arnatar Therapeutics risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- Arnatar Therapeutics ARR
- Arnatar Therapeutics revenue
- Arnatar Therapeutics valuation
- unit economics
Team and culture
Founders, leadership, and org.
- Arnatar Therapeutics founders
- Arnatar Therapeutics CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
Analysis based on structured company profile data and public funding records.